News Search Results
Apr 30, 2025, 16:00 ET Rgenta Therapeutics Announces Presentation of Preclinical Data from Proprietary RSwitch Technology at the American Society of Gene And Cell Therapy (ASGCT) 2025 Annual Meeting
Mass., April 30, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
Apr 30, 2025, 15:17 ET Fluorescence Microscopy Market to Reach $1.3 Billion by 2029
targeted therapies. Understanding Cellular Processes: Real-time observation of cellular mechanisms helps in medical research and biotechnology advances. Research Funding: Increased funding supports new technologies, equipment, and researcher training. Miniaturization:
More news about: BCC Research LLC
Apr 30, 2025, 10:30 ET Surface Disinfectant Market worth US$4.38 billion by 2030 with 7.6% CAGR | MarketsandMarkets™
on end user, the surface disinfectant market is segmented into hospitals, clinics, and ASCs, diagnostic laboratories, pharmaceutical & biotechnology companies, and research laboratories. The hospitals, clinics, and ASCs segment is expected to grow at the fastest CAGR during the forecast period.
More news about: MarketsandMarkets
Apr 30, 2025, 09:05 ET Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer
DIEGO, April 30, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing personalized, autologous cell therapies, has appointed Dalen Meeter, CPA, MBA, as Chief Financial
More news about: Aspen Neuroscience, Inc.
Apr 30, 2025, 08:33 ET Ingenium Therapeutics Receives FDA Feedback Enabling Direct Phase 2 Trial for Gengleucel in MRD+ AML
Ingenium Therapeutics, a clinical-stage biotechnology company advancing allogeneic natural killer (NK) cell therapies, today announced that it has received positive regulatory feedback from the U.S.
More news about: Ingenium Therapeutics
Apr 30, 2025, 08:05 ET INOVIO to Present at Upcoming Scientific and Investor Conferences
MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Apr 30, 2025, 08:00 ET Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor
More news about: Anixa Biosciences, Inc.
Apr 30, 2025, 08:00 ET CellFE® Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular Therapies
www.cellfebiotech.com. About TcellTech TCellTech GmbH is a clinical-stage biotechnology company founded in 2022 as a spin-out from the German Cancer Research Center (DKFZ) and is focused on developing universal, personalized adoptive
More news about: CellFE
Apr 30, 2025, 07:30 ET Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid
Conn., April 30, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT), an organization working to cure Rett Syndrome,
More news about: Apertura Gene Therapy
Apr 30, 2025, 07:30 ET Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Apr 30, 2025, 07:00 ET Avista Therapeutics Announces Oral Presentation at Association for Research in Vision and Ophthalmology 2025 Annual Meeting
Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today announced that the Company will present data highlighting the
More news about: Avista Therapeutics
Apr 30, 2025, 06:59 ET Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Apr 30, 2025, 03:11 ET Genocury Biotech Announces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
approach." About Genocury Biotech Shenzhen Genocury Biotech Co., Ltd. is a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress™ platform. This modular delivery system enables targeted delivery
More news about: Genocury Biotech
Apr 29, 2025, 14:06 ET NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting
29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor cell vaccine (NGEN-143) activates T cells that recognize a diverse antigen repertoire.
More news about: NEUVOGEN, Inc.
Apr 29, 2025, 13:10 ET Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer
Transneural Therapeutics, Inc. (Transneural), a preclinical-stage biotechnology company aiming to transform the treatment of neuropsychiatric and neurodegenerative diseases with novel neuroplastogens, announced the appointment
More news about: Transneural Therapeutics, Inc.
Apr 29, 2025, 12:50 ET Hydrocolloids Market Set to Reach $10.42 Billion by 2029 - Growth Driven by Innovations in Food & Pharmaceuticals | Valuates Reports
vegan-friendly ingredients has led to a rise in agar applications in confectionery, bakery, and dessert sectors. Additionally, the pharmaceutical and biotechnology sectors utilize agar for microbial culture media preparation. The natural origin of carrageenan and agar also aligns well with the clean-label movement
More news about: Valuates Reports
Apr 29, 2025, 11:15 ET Marengo Presents Expanded Clinical Monotherapy Activity of Invikafusp Alfa in Multiple PD-1 Resistant Tumors as a Clinical Plenary Oral at AACR 2025
April 29, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy, today announced new clinical and translational data from the ongoing STARt-001
More news about: Marengo Therapeutics
Apr 29, 2025, 10:10 ET Hoofprint Biome Raises $15M to Cut Methane and Boost Yield in Cattle
the rumen, and it's natural?" "Nature has spent millions of years evolving proteins as tools to regulate microbial growth. Biotechnology and artificial intelligence have finally gotten to the point where we can actually turn nature's tools into viable commercial products," says
More news about: Hoofprint Biome
Apr 29, 2025, 10:07 ET Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic
More news about: Kytopen
Apr 29, 2025, 10:05 ET Active Pharmaceutical Ingredients (API) Market to Amass $359.45 Billion by 2030 at CAGR 5.85% - Grand View Research, Inc.
projected to grow at a CAGR of 4.7% from 2024 to 2030. This growth is attributed to the increasing demand for innovative medicines, advancements in biotechnology, and the shift towards microbial-based fermentation approaches. In addition, the rising need for environmentally friendly production methods and
More news about: Grand View Research, Inc.
Apr 29, 2025, 09:30 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Apr 29, 2025, 09:30 ET Appian Celebrates 2025 Innovation Award Winners
Regeneron: A leading biotechnology firm has created a cutting-edge clinical trial feasibility platform. Using multiple Appian capabilities, this technology delivers an innovative
More news about: Appian
Apr 29, 2025, 09:30 ET Appian Celebrates 2025 Innovation Award Winners
Regeneron: A leading biotechnology firm has created a cutting-edge clinical trial feasibility platform. Using multiple Appian capabilities, this technology delivers an innovative
More news about: Appian
Apr 29, 2025, 09:00 ET Spiderwort Biotechnologies Inc. Announces Status of Biocompatibility Testing for CelluJuve®
April 29, 2025 /PRNewswire/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced the completion of ISO 10993 biocompatibility testing and human skin safety
More news about: Spiderwort Biotechnologies Inc.
Apr 29, 2025, 09:00 ET Gifthealth Appoints Chip Parkinson as Chief Executive Officer to Accelerate Growth and Innovation in Pharmacy Services
Chief Executive Officer. A veteran healthcare executive with three decades of experience, Parkinson brings deep leadership expertise across biotechnology, pharmacy benefit management, diagnostics, and pharmaceutical industries. His extensive background includes spearheading billion-dollar portfolios
More news about: Gifthealth